| Hope for new cancer therapies
The team is absolutely on the mark with this work. It's enormously promising,'' said Erik Thompson, a breast cancer scientist with St Vincent's Institute and the University of Melbourne. That's so, he said, as the group - led by Joan Massague, head of the cancer biology and genetics program at the Memorial Sloan-Kettering Cancer Center in New York - have revealed key steps breast cancer cells take when they spread to the lungs and bone in a process called metastasis. "Metastasis is what's killing people with cancer,'' said Associate Professor Thompson. "The pathways which allow tumour cells to spread through the body and stay there, resistant to chemotheraphy, are exactly the pathways we have to understand and conquer,'' claimed Professor Thompson. Melbourne-based oncologist and breast cancer scientist Geoff Lindeman agreed, but cautioned that the findings must be proven in clinical trials.
Britney Spears fails to regain lost visitation rights
BRITNEY Spears will not be able to visit her sons at least until her next custody hearing in February and K-Fed has full custody until April. TMZ.com reports that Commissioner Scott Gordon ruled against restoring the visitation rights she lost after the four hour standoff with emergency services a few weeks ago. The Commissioner heard evidence from several other witnesses, including Spears's ex-husband Kevin Federline, two LAPD cops who responded to a custody standoff a week ago Thursday; a parenting coach; a bodyguard, and the court monitor who was present during the drama. PageSix.com reports that the January 4 emergency order which gave Federline custody of sons Sean and Jayden was extended today until April. Britney arrived more than three hours late amid chaos at the courthouse packed with a media throng.
Jessica Sierra sentenced to 1 year in rehab
TAMPA, Fla. - A judge is sending Jessica Sierra to rehab. The former "American Idol" contestant was sentenced Monday to a yearlong stint at a California rehabilitation clinic and three years' probation. Sierra, 22, was arrested last month for disorderly intoxication and resisting officers. She remained jailed Tuesday in Tampa. .
Boosters slow to join GOP race
Bill Richardson, a Democrat, because he was the only Hispanic running for the White House. "I think as a Latino, we all have a responsibility to back qualified Latinos," Sosa said. After Richardson's withdrawal from the race, Sosa threw his support behind McCain, largely because of his stance on immigration reform. But while many of Bush's one-time South Texas backers have flocked to McCain, Giuliani and Romney, others appear to be waiting for a consensus candidate to emerge. "There is a wait-and-see attitude out there," J. Bruce Bugg Jr. said. Bugg, a San Antonio investment banker, is a member of the McCain campaign's South Texas finance committee. He said victories by former Arkansas Gov.
Helping women start tech firms
Kris Appel stood before investors this week and delivered a seven-minute pitch on the market viability of an exercise device that helps stroke survivors regain their arm movement.
The presentation at a biosciences conference in Baltimore was Appel's latest effort to raise money for her startup company, which grew out of a program that trains and helps women start technology-based businesses.
Called ACTiVATE, the backbone of the program gives women access to technology and research created by the region's laboratories and universities with a goal of commercializing such homegrown innovations. Since its start in 2005, the program at the University of Maryland, Baltimore County has produced 12 startups, including Appel's.
.
Bloggers weigh the Iowa caucus results.
I had to watch the Obama speech twice to be sure: But at a moment early in his oration, his crowd responded by shouting, 'USA! USA!'" he writes at the Plank. "I've been slow to fall for Obama. … Still, his emphasis on the 'nation'—one of his most recurrent themes—is also one of his most appealing. I don't think I've ever heard a crowd of Democratic primary voters erupt in a spontaneous display like this. It was a genuinely moving moment, and another leading indicator of his electibility." .
Open Mike: Tiger always a hot topic
My irons were not sharp." I agree that the man carries a lot of weight on his shoulders and a lot of responsibility. That is exactly why, if he chooses once in awhile not to answer all the questions from inquiring minds, it is his right. I think we expect too much of him anyway. . . .
New Tech fan blog: 'Shake and Bake' cooking up great future with ...
JASON JONES: Louisiana Tech begins the new year at 3-9 and will look to start the WAC portion of its schedule with a win over the visiting Fresno State Bulldogs. Tech just completed an impressive 10-point win over McNeese State in which true freshman Dwayne Lathan broke out with 19 points, five rebounds, and two steals in 19 minutes. The Tech Bulldogs held the Cowboys to 38% shooting for the game including 28% in the first half. Fresno State arrives after a seven-point loss to Stanford that brings it to 7-6 overall and 1-5 on the road. The California Bulldogs are led by 5-10 guard Kevin Bell who was picked second team all WAC in the preseason and is averaging 17.5 points per game. Fellow guards Eddie Miller and Bryan Harvey also average in double figures while 6-9senior post Hector Hernandez leads the team with 6.9 rebounds to go with his 10.8 points per game.
New Clinical Trial Results Show How Personalized Medicine Will Alter ...
ScienceDaily (Jan. 2, 2008) One of the nation's pre-eminent genetic researchers, Eric Hoffman, PhD, of Children's Research Institute at Children's National Medical Center, predicts that in relatively short order, medicine's next innovation--individualized molecular therapies--will have the unprecedented ability to treat muscular dystrophies, and other disorders. .
Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck/Schering-Plough Pharmaceuticals announced today the primary endpoint and other results of the ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) trial. Merck/Schering-Plough has submitted an abstract on the ENHANCE trial for presentation at the American College of Cardiology meeting, which will be held in March 2008, and is awaiting notification of acceptance from the College. .
|
